Literature DB >> 25349122

Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene.

Mark J Canet1, Matthew D Merrell1, Bryan G Harder1, Jonathan M Maher1, Tongde Wu1, Andrew J Lickteig1, Jonathan P Jackson1, Donna D Zhang1, Masayuki Yamamoto1, Nathan J Cherrington2.   

Abstract

The ATP-binding cassette (ABC) family of transporters, including ABCC3, is a large family of efflux pumps that plays a pivotal role in the elimination of xenobiotics from the body. ABCC3 has been reported to be induced during hepatic stress conditions and through the progression of some forms of cancer. Several lines of evidence have implicated the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in this induction. However, although rodent models have been investigated, a functional antioxidant response element (ARE) in the human ABCC3 gene has not been identified. The purpose of this study was to identify and characterize the ARE(s) responsible for mediating the Nrf2-dependent induction of the human ABCC3 gene. A high-throughput chromatin immunoprecipitation-sequencing analysis performed in A549 cells revealed a specific interaction between Nrf2 and the eighth intron of the human ABCC3 gene rather than the more prototypical flanking region of the gene. Subsequent in silico analysis of the intron identified two putative ARE elements that contained the core consensus ARE sequence commonly found in several Nrf2-responsive genes. Functional characterization of these two AREs using luciferase-reporter constructs with ARE mutant constructs revealed that one of these putative AREs is functionally active. Finally, DNA pull-down assays confirmed specific binding of these intronic AREs by Nrf2 in vitro. Our findings identify a functional Nrf2 response element within the eighth intron of the ABCC3 gene, which may provide mechanistic insight into the induction of ABCC3 during antioxidant response stimuli.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25349122      PMCID: PMC4279086          DOI: 10.1124/dmd.114.060103

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  36 in total

1.  Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.

Authors:  Hairong Huo; Pellegrino G Magro; E Christy Pietsch; Brijesh B Patel; Kathleen W Scotto
Journal:  Cancer Res       Date:  2010-09-22       Impact factor: 12.701

2.  Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.

Authors:  Christopher M Mahaffey; Nichole C Mahaffey; William Holland; Hongqiao Zhang; David R Gandara; Philip C Mack; Henry Jay Forman
Journal:  J Thorac Oncol       Date:  2012-01       Impact factor: 15.609

3.  MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas.

Authors:  Hidefumi Sasaki; Masayuki Shitara; Keisuke Yokota; Yu Hikosaka; Satoru Moriyama; Motoki Yano; Yoshitaka Fujii
Journal:  Mol Med Rep       Date:  2012-07-05       Impact factor: 2.952

4.  Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis.

Authors:  M Ananthanarayanan; Yanfeng Li; S Surapureddi; N Balasubramaniyan; Jaeyong Ahn; J A Goldstein; Frederick J Suchy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-17       Impact factor: 4.052

5.  Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival.

Authors:  Jiansheng Wang; Mingxin Zhang; Lingmin Zhang; Hui Cai; Suna Zhou; Jia Zhang; Yang Wang
Journal:  J Surg Res       Date:  2010-06-16       Impact factor: 2.192

6.  Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice.

Authors:  Lauren M Aleksunes; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2012-04-11       Impact factor: 3.922

7.  High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease.

Authors:  Jenny E Ros; Louis Libbrecht; Mariska Geuken; Peter L M Jansen; Tania A D Roskams
Journal:  J Pathol       Date:  2003-08       Impact factor: 7.996

8.  Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.

Authors:  Gernot Zollner; Peter Fickert; Dagmar Silbert; Andrea Fuchsbichler; Hanns Ulrich Marschall; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

9.  Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites.

Authors:  A L Slitt; N J Cherrington; J M Maher; C D Klaassen
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

10.  Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.

Authors:  Rhiannon N Hardwick; Craig D Fisher; Mark J Canet; George L Scheffer; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2011-08-30       Impact factor: 3.922

View more
  10 in total

Review 1.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

2.  Nrf2 Ameliorates DDC-Induced Sclerosing Cholangitis and Biliary Fibrosis and Improves the Regenerative Capacity of the Liver.

Authors:  Athanassios Fragoulis; Julia Schenkel; Miriam Herzog; Tim Schellenberg; Holger Jahr; Thomas Pufe; Christian Trautwein; Thomas W Kensler; Konrad L Streetz; Christoph Jan Wruck
Journal:  Toxicol Sci       Date:  2019-06-01       Impact factor: 4.849

3.  ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.

Authors:  Lingjie Bao; Jianfa Wu; Matthew Dodson; Elisa Montserrat Rojo de la Vega; Yan Ning; Zhenbo Zhang; Ming Yao; Donna D Zhang; Congjian Xu; Xiaofang Yi
Journal:  Mol Carcinog       Date:  2017-05-02       Impact factor: 4.784

4.  The trypanocidal benznidazole promotes adaptive response to oxidative injury: Involvement of the nuclear factor-erythroid 2-related factor-2 (Nrf2) and multidrug resistance associated protein 2 (MRP2).

Authors:  Juan Pablo Rigalli; Virginia Gabriela Perdomo; Nadia Ciriaci; Daniel Eleazar Antonio Francés; María Teresa Ronco; Amy Michele Bataille; Carolina Inés Ghanem; María Laura Ruiz; José Enrique Manautou; Viviana Alicia Catania
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-12       Impact factor: 4.219

5.  Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.

Authors:  Peng-Cheng Li; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek; Zhijian Duan; Qian-Yu Zhang; Ai-Xi Yu; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2017-10-23       Impact factor: 3.922

Review 6.  Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance.

Authors:  In-geun Ryoo; Sang-hwan Lee; Mi-Kyoung Kwak
Journal:  Oxid Med Cell Longev       Date:  2015-11-22       Impact factor: 6.543

7.  Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.

Authors:  L Torrente; C Sanchez; R Moreno; S Chowdhry; P Cabello; K Isono; H Koseki; T Honda; J D Hayes; A T Dinkova-Kostova; L de la Vega
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

8.  A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations.

Authors:  Daniel C Levings; Xuting Wang; Derek Kohlhase; Douglas A Bell; Matthew Slattery
Journal:  Redox Biol       Date:  2018-08-22       Impact factor: 11.799

Review 9.  Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer.

Authors:  Xiao-Yu Yan; Xian-Zhi Qu; Long Xu; Si-Hang Yu; Rui Tian; Xin-Ru Zhong; Lian-Kun Sun; Jing Su
Journal:  Cancer Cell Int       Date:  2020-04-16       Impact factor: 5.722

10.  ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy.

Authors:  Serena Pellegatta; Natalia Di Ianni; Sara Pessina; Rosina Paterra; Elena Anghileri; Marica Eoli; Gaetano Finocchiaro
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.